ESMO 2026: PROSPER: A first in human study of FMC-376, a KRAS G12C equipotent ON+OFF inhibitor in patients with advanced KRAS G12C mutant solid tumors, with a focus on NSCLC

ESMO 2026: PROSPER: A first in human study of FMC-376, a KRAS G12C
equipotent ON+OFF inhibitor in patients with advanced KRAS G12C
mutant solid tumors, with a focus on NSCLC

The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC